Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Cardiac Valve Pathogens Detected by Multiplex Assay

By LabMedica International staff writers
Posted on 14 Jan 2014
Infective endocarditis (IE) is a life-threatening condition burdened by high mortality, and gram-positive cocci account for the majority of the cases. More...


Blood culture represents a cornerstone for the microbiological diagnosis of IE, but it can be negative in a substantial number of patients. Similarly, culture of excised cardiac valves can be burdened by a considerable number of false negative results, mostly in patients under antibiotic therapy, or by false positive results, due to contamination.

Microbiologists at the University of Perugia (Italy) carried out a proof of concept study using a commercially available multiplex real-time polymerase chain reaction (PCR) for the detection of pathogens in cardiac valves from patients with infective endocarditis. Between June 2011 and January 2013, 20 cardiac valves, 11 mitral and 9 aortic excised from an equal number of patients with definite IE diagnosis of known etiology were tested by conventional culture and the real-time PCR test. Five aortic valves excised from non-IE patients, affected by noninfective cardiac complications, were included in the study as controls. Mean age of the patients was 64.2 years and all patients were on antimicrobial therapy during sampling.

All excised valves were examined with Gram stain and inoculated into culture media. The commercially available SeptiFast real-time-PCR system (Roche Molecular Systems; Mannheim, Germany) was evaluated as a diagnostic tool for IE and was performed in Roche Diagnostics’ LightCycler instrument. An organism detected by SeptiFast (SF) test was considered true pathogen if it coincided with the infectious agent previously isolated from blood culture, collected from the same IE patient.

The SeptiFast test gave a positive result in 19 out of 20 valves from patients with IE, and a negative result in all the five valves from non-IE patients. In all cases, the organism detected by the test was concordant with the known etiologic agent and Gram staining. Culture was positive in 3 out of 20 valves from IE patients, for microorganisms matching those previously isolated from blood culture and was negative in all valves from non-IE patients, and therefore culture sensitivity was only 15.8%, and specificity was 100%. Gram staining was positive in 16 valves from IE patients, and negative in all non-IE patients.

The authors concluded that the SeptiFast (SF) assay can be used on culture-negative heart valve tissues, excised from patients with IE, showing sensitivity and negative predicative value (NPV) higher than culture, with the same high specificity and positive predictive value (PPV). In cases of SF positive for coagulase-negative staphylococci (CoNS) or streptococci, a DNA sequencing of the amplicons would be required to identify the pathogen at the species level. In case of negative SF result, it would be advisable to test cardiac valves by PCR procedures specific for uncommon infectious agents of IE. The study was published on December 21, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

University of Perugia
Roche Molecular Systems 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.